Press Room

2021 Online Booth

Start
Thursday, September 30, 2021 - 00:00
End
Saturday, October 30, 2021 - 00:00
Location: online
Hovione Virtual Stand 2021 Online Booth | Hovione

Meet our experts at the pharma industry-leading events

 

We attend the leading events of the pharma industry throughout the year to present our Services & Products, sharing our scientists' innovative work.

Count on our multidisciplinary teams to understand, develop and improve your project. As a specialist integrated CDMO we are dedicated to helping you bring new and off-patent drugs to market faster.

Schedule an in-person meeting or virtual conversation beforehand and find out how we can support your project.

 

 

Hovione at a Glance | Hovione

Get to know more about our history

e-Brochures | Hovione

Explore what we do

Integrated CDMO | Hovione

Webinars, Articles & More

Cork Site | Hovione

We welcome you to our sites

Events | Hovione

Events will be attending

Analytical Development | Hovione

Our experts will help you

 

 

SOLVING YOUR CHALLENGES

Read the article from C&EN "One molecule’s journey from discovery to market" to find out how Hovione helped one customer solve their problem and succeed. More case studies will be available soon.

 

 

Subscribe to our newsletter and be the first to know.

 

 

 

 

 

Also in the Press Room

See All

Continuous Tableting (CT) is defined as continuous manufacturing of oral dose drugs, specifically tablets. As per ICH's Q13 definition1, a continuous manufacturing process in the pharmaceutical industry comprises at least two unit operations integrated from a mechanical and software perspective. There is a wide combination of possible CT process configurations that are dependent on the needs of the intended product formulation and each of the individual unit operations that constitute the process train can be continuous, semi-continuous, or batch processes. The typical manufacturing processes for tablet formulation are direct compression (DC), dry granulation (DG) and wet granulation (WG)2 - details on these manufacturing processes are beyond the scope of this article, so the interested reader is directed to relevant literature. The actual implementation of CT technology in a facility can broadly vary depending on the level of desired integration and automation. Process trains can be designed to be flexible and converted between multiple configurations (e.g. continuous DC, DG and WG), controlled by the end user from one single software and within a single clean room. The other possibility would be for subsections of the CT process to be divided into multiple clean rooms where inprocess materials are transferred between suites via a bin-to-bin approach (e.g. a granulation suite to prepare granules from raw materials followed by continuous DC (CDC) to blend the granules and produce tablets). The level of automation and instrumentation designed into the CT process (typically involving Process Analytical Technologies, PAT) can open the possibility to implement sophisticated control strategies. Key components of a control strategy that need to be considered for CT are material tracking and genealogy, knowledge of the residence time distribution (RTD), and in-process controls (spectroscopic and/or soft sensors based on process parameters). Holistically, these control strategy elements enable the implementation of a material diversion strategy to automatically divert out of specification material from the process. In their most advanced form, control strategies may also enable real time release testing (RTRt) of the final tablet drug product and reduce the off-line analytical burden and the number of operators needed to manage the process.   Read the full article at gmp-journal.com  

Article

Continuous Tableting and the Road to Global Adoption

Mar 04, 2024